ALTRENO

Peak

tretinoin

NDATOPICALLOTION

Approved

Aug 2018

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

nucleus. Tretinoin activates three members of the retinoic acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are…

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT07341659N/AActive Not Recruiting

Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.

Started Feb 2025

102 enrolled

Acne

NCT04353180Phase 3Unknown

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)

Started Aug 2021

100,000 enrolled

COVID19

NCT04096742Phase 4Unknown

Altreno for Chest Rejuvenation

Started Aug 2019

40 enrolled

Photodamaged SkinPhotoaging

NCT02498288Phase 1Completed

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Started May 2013

36 enrolled